INSULIN-ANTIBODIES AND INSULIN AUTOANTIBODIES

[1] Van Haeften T., Clinical significance of insulin antibodies in insulin‐treated diabetic patients, Diabetes Care, 12, pp. 641-648, (1989)

[2] Heding LG, Larsson Y., Ludvigsson J., The immunogenicity of insulin preparation. Antibody levels before and after transfer to highly purified porcine insulin, Diabetologia, 19, pp. 511-515, (1980)

[3] Wilson RM, Douglas CA, Tattersall RB, Reeves WG, Immunogenicity of highly purified bovine insulin: a comparison with conventional bovine and highly purified human insulins, Diabetologia, 28, pp. 667-670, (1985)

[4] Zinman B., Medical intelligence drug therapy. The physiologic replacement of insulin, N Engl J Med, 321, pp. 363-370, (1989)

[5] Heding LG, Marshall MO, Persson B., Dahlquist G., Et al., Immunogenicity of monocomponent human porcine insulin in newly diagnosed type I (insulin dependent) diabetic children, Diabetologia, 27, pp. 96-98, (1984)

[6] Fineberg SE, Galloway JA, Fineberg NS, Rathbun MJ, Hufferd S., Immunogenicity of recombinant DNA human insulin, Diabetologia, 25, pp. 465-469, (1983)

[7] Kumar D., Insulin antibodies: an analysis of immunoglobulin G subclasses (Abstract), Diabetes, 35, (1986)

[8] Dorchy H., Duchateau J., Bosson D., D'Hooge D., Transfer from purified porcine insulins to semisynthetic human insulins decreases insulin antibodies and circulating immune complexes in diabetic children and adolescents. A two‐year follow‐up, Diabete Metabol, 15, pp. 107-110, (1989)

[9] Marshall MO, Heding LG, Villumsen J., Akerblom HK, Et al., Development of insulin antibodies, metabolic control and B‐cell function in newly diagnosed insulin dependent diabetic children treated with monocomponent human insulin or monocomponent porcine insulin, Diabetes Res, 9, pp. 169-175, (1988)

[10] Eichner HL, Lauritano AA, Woertz LL, Selam J-L, Gupta S., Charles MA, Cellular immune alterations associated with human insulin therapy, Diabetes Res, 8, pp. 111-115, (1988)

[1] Van Haeften T., Clinical significance of insulin antibodies in insulin‐treated diabetic patients, Diabetes Care, 12, pp. 641-648, (1989)

[2] Heding LG, Larsson Y., Ludvigsson J., The immunogenicity of insulin preparation. Antibody levels before and after transfer to highly purified porcine insulin, Diabetologia, 19, pp. 511-515, (1980)

[3] Wilson RM, Douglas CA, Tattersall RB, Reeves WG, Immunogenicity of highly purified bovine insulin: a comparison with conventional bovine and highly purified human insulins, Diabetologia, 28, pp. 667-670, (1985)

[4] Zinman B., Medical intelligence drug therapy. The physiologic replacement of insulin, N Engl J Med, 321, pp. 363-370, (1989)

[5] Heding LG, Marshall MO, Persson B., Dahlquist G., Et al., Immunogenicity of monocomponent human porcine insulin in newly diagnosed type I (insulin dependent) diabetic children, Diabetologia, 27, pp. 96-98, (1984)

[6] Fineberg SE, Galloway JA, Fineberg NS, Rathbun MJ, Hufferd S., Immunogenicity of recombinant DNA human insulin, Diabetologia, 25, pp. 465-469, (1983)

[7] Kumar D., Insulin antibodies: an analysis of immunoglobulin G subclasses (Abstract), Diabetes, 35, (1986)

[8] Dorchy H., Duchateau J., Bosson D., D'Hooge D., Transfer from purified porcine insulins to semisynthetic human insulins decreases insulin antibodies and circulating immune complexes in diabetic children and adolescents. A two‐year follow‐up, Diabete Metabol, 15, pp. 107-110, (1989)

[9] Marshall MO, Heding LG, Villumsen J., Akerblom HK, Et al., Development of insulin antibodies, metabolic control and B‐cell function in newly diagnosed insulin dependent diabetic children treated with monocomponent human insulin or monocomponent porcine insulin, Diabetes Res, 9, pp. 169-175, (1988)

[10] Eichner HL, Lauritano AA, Woertz LL, Selam J-L, Gupta S., Charles MA, Cellular immune alterations associated with human insulin therapy, Diabetes Res, 8, pp. 111-115, (1988)